Przejdź do zawartości
Merck

A hereditary bleeding disorder resulting from a premature stop codon in thrombomodulin (p.Cys537Stop).

Blood (2014-07-23)
Jonathan Langdown, Roger J Luddington, James A Huntington, Trevor P Baglin
ABSTRAKT

In this study, we describe a novel thrombomodulin (TM) mutation (c.1611C>A) that codes for a change from cysteine 537 to a premature stop codon (p.Cys537Stop). Three members of a family with a history of posttraumatic bleeding were identified to be heterozygous for this TM mutation. All coagulation screening tests, coagulation factor assays, and platelet function test results were within normal limits. However, the endogenous thrombin potential was markedly reduced at low-tissue factor concentration, and failure to correct with normal plasma indicated the presence of a coagulation inhibitor. Plasma TM levels were highly elevated (433-845 ng/ml, normal range 2-8 ng/ml, equating to 5 to 10 nM), and the addition of exogenous protein C further decreased thrombin generation. The mutation, p.Cys537Stop, results in a truncation within the carboxyl-terminal transmembrane helix. We predict that as a consequence of the truncation, the variant TM is shed from the endothelial surface into the blood plasma. This would promote systemic protein C activation and early cessation of thrombin generation within a developing hemostatic clot, thereby explaining the phenotype of posttraumatic bleeding observed within this family.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Sodium Citrate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O
Sigma-Aldrich
Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
Sigma-Aldrich
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, ≥97.0% (TLC)
Sigma-Aldrich
Transferrin human, Optiferrin, recombinant, expressed in rice
Sigma-Aldrich
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, ≥99.0% (10 mg phospholipid per ml CHCl3, TLC)